HCW Biologics advances TRBC-pembrolizumab immune checkpoint inhibitor for solid tumor trials

HCW Biologics, a clinical-stage biopharmaceutical company, has designated one of its proprietary TRBC-pembrolizumab-based immune checkpoint inhibitors as its franchise immunotherapeutic to be advanced into internal clinical development for treating solid tumours. The company said that this lead candidate, HCW11-040, is a multifunctional fusion protein incorporating pembrolizumab alongside interleukin-7, interleukin-15, and TGF-β receptor trap elements. According […] The post HCW Biologics advances TRBC-pembrolizumab immune checkpoint inhibitor for solid tumor trials appeared first on Longevity.Technology.